Publisher
Springer Science and Business Media LLC
Reference287 articles.
1. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
2. Poulikakos, P. I., Sullivan, R. J. & Yaeger, R. Molecular pathways and mechanisms of BRAF in cancer therapy. Clin. Cancer Res. 28, 4618–4628 (2022).
3. Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M. & Watson, I. R. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene 37, 3183–3199 (2018).
4. Food & Drug Administration. FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. FDA www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid (2022).
5. Corcoran, R. B. et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J. Clin. Oncol. 33, 4023–4031 (2015).